Brokerage Firm Rating on Cempra (CEMP)

Cempra (CEMP) : 9 brokerage houses believe that Cempra (CEMP) is a Strong Buy at current levels. 1 Analyst considers the fundamentals to be worthy of a Buy recommendation. 1 analysts believe that the current prices are in a balance with the stocks fundamentals, hence they propose Hold on Cempra (CEMP). Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 11 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.23.

Cempra (CEMP) has been rated by 10 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $51 and the lowest price target forecast is $23. The average forecast of all the analysts is $38.2 and the expected standard deviation is $8.03.


For the current week, the company shares have a recommendation consensus of Buy. Cempra (NASDAQ:CEMP): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.01 and $22.75 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $23.82. The buying momentum continued till the end and the stock did not give up its gains. It closed at $23.56, notching a gain of 3.47% for the day. The total traded volume was 929,009 . The stock had closed at $22.77 on the previous day.

In a related news, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the officer (Chief Commercial Officer) of Cempra, Inc., Moore David, had purchased 500 shares in a transaction dated on March 1, 2016. The transaction was executed at $16.18 per share with total amount equaling $8,090.

Cempra Inc. is a clinical-stage pharmaceutical company focused on developing differentiated antibiotics for the acute care and community settings to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic staphylococcal infections. The Companys lead product, solithromycin, is being developed in oral capsules, intravenous, or IV, and suspension formulations, initially for the treatment of community acquired bacterial pneumonia, or CABP, an infection of the respiratory tract. The Companys second product is Taksta, an antibiotic known as fusidic acid, that has been used for decades outside the United States, including Western Europe, but , which has never been approved in the United States. The Company is developing Taksta in the United States as an oral treatment of refractory bone and joint infections caused by staphylococci.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.